When it comes to Canadian companies that have reached worldwide success in the health care sector, Bausch Health Companies Inc. (Bausch Health) stands amongst the tallest. However, even with more than $4 billion in annual export value from its Canadian facilities and a global reputation for quality and innovation, Bausch Health also remains focused on the development, distribution, and manufacturing of pharmaceutical products and technologies for Canadians, right here in Canada.

“From a quality perspective, we are very proud of the output from our Canadian manufacturing plants,” says Richard Lajoie, President, Canada, Bausch Health. “Our excellent manufacturing infrastructure in Canada allows us to produce products locally with remarkable speed, which ultimately results in faster access for patients.”

With the company’s global corporate head office based in Laval, Québec, and Canadian Bausch + Lomb administrative offices in Vaughan, Ontario, Bausch Health employs approximately 1,000 Canadians.

Bausch Health brought two new treatment innovations to the Canadian market this year. The first is an innovative treatment for chronic weight management in adults (obese and overweight with weight-related comorbidities), and the second is an important new option that helps treat moderate to severe psoriasis in adults.

Canadian manufacturing presence is a key to global success

While eye care may be what many think of when hearing the company’s name, in reality, Bausch Health is much more. A tireless and focused effort on improving people’s lives with high-quality, accessible health care products has enabled the company to achieve significant growth.

Globally, Bausch Health now has approximately 21,000 employees. The company develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products focused on the therapeutic areas of eye health, gastroenterology, and dermatology.

Canadian operations contribute significantly to this worldwide success. More than 300 high-quality products are manufactured in award-winning facilities in Steinbach, Manitoba and Laval, Québec and are then shipped out around the world.

“Our Canadian operations are a big part of how we have managed to earn our global reputation for producing high-quality, innovative health products,” explains Lajoie.

R&D is an important component to the company’s future

Bausch Health practices an output-focused research and development model in which efficiency drives growth. By focusing on critical skills and areas of established capabilities, it is able to dedicate significant and meaningful resources to research and development. Investment in R&D is expected to increase globally as a priority for the company in the coming years.

“As we successfully bring new innovations to market that improve patient health, we will boost the company’s revenues and bottom line, which in turn, will enable us to re-invest in R&D for more new treatments that can help patients around the world,” says Joseph C. Papa, Chairman and CEO of Bausch Health.

Further emphasizing the company’s commitment to Canadian patients, are new prescription treatments for glaucoma and a topical to treat psoriasis that are being prepared to launch in Canada.

Bringing forward innovative new health care products for Canadians

In Canada, Bausch Health has brought two new treatment innovations to the market this year. The first is an innovative treatment for chronic weight management in adults (obese and overweight with weight-related comorbidities), and the second is an important new option that helps treat moderate to severe psoriasis in adults. New prescription treatments for glaucoma and a topical to treat psoriasis are being prepared to launch in Canada.

The company continues to build product lines and expand its reach into emerging markets while recognizing the importance of its strong Canadian hub with its an enhanced manufacturing presence.